XXXX , @entity2645 , and @entity11440 in the Treatment of Primary Nocturnal Enuresis: A Randomized Clinical Trial.

@entity1 @entity7062 @entity2645 @entity11440
BACKGROUND: Nocturnal enuresis is the most common pediatric urologic problem in outpatient clinics. OBJECTIVES: To assess the effect of various monotherapies, and comparing the effects of @entity7062 , @entity2645 , and @entity11440 in @entity1 with enuresis, as well as the influence of socioeconomic and cultural factors of their families on the response and relapse rates. @entity1 AND METHODS: The study was a randomized clinical trial conducted on 92 @entity1 aged 5 - 14 years, referred to the pediatric clinic of Semnan University Hospital in Semnan, Iran. @entity1 with primary nocturnal enuresis were randomly allocated to three different treatment groups: @entity7062 (n = 30), @entity2645 (n = 31), and @entity11440 (n = 31) all for 6 weeks. The socioeconomic and demographic characteristics of all @entity1 were recorded. The number of wet nights per week was noted at the end of the 6-week-trial, and @entity1 were followed up to three months for relapse. RESULTS: @entity1 in the @entity11440 group showed a slightly higher response rate (71.0% success) and a lower relapse rate (31.8%), while in the @entity7062 group the response and relapse rates were 63.3% and 57.9%, respectively, and in the @entity2645 group 61.3% and 63.2%, respectively. However, the difference between the 3 groups in terms of response (P = 0.701) and relapse rates (P = 0.095) was not statistically significant. CONCLUSIONS: There is no significant difference between monotherapy with @entity7062 , @entity2645 or @entity11440 in @entity1 with enuresis. However, @entity11440 showed a higher response rate and a lower relapse rate compared to other medications. More clinical trials with a larger sample size are needed to clarify these uncertainties.
